Getinge earns reinstated CE mark for intra-aortic balloon pump
August 4, 2025
Getinge announced today that European regulatory authorities reinstated the CE mark for its Cardiosave intra-aortic balloon pump.
Getinge announced today that European regulatory authorities reinstated the CE mark for its Cardiosave intra-aortic balloon pump.
In a study published in Advanced Materials, a research team developed an innovative bacterial cellulose (BC)-based hemostatic dressing that enables rapid and sustained bleeding control.
By understanding differences in how people’s brains are wired, clinicians may be able to predict who would benefit from a self-guided anxiety care app, according to a new analysis from a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Carlsmed (Nasdaq:CARL) today announced new technology add-on payment (NTAP) reimbursement for its spine implant technology.
Biomedical and genetic engineers at Duke University and the Albert Einstein College of Medicine have developed a technique that naturally increases the presence of a light-sensitive molecule throughout the body.
About one quarter of patients with muscle-invasive bladder cancer (MIBC) may be treated and derive a benefit with the current standard chemotherapy. To better understand why some tumors resist chemotherapy and identify better ways to treat those cancers, researchers at Baylor College of Medicine have conducted a detailed molecular analysis of MIBC tumors.
Heart attacks remain a leading cause of death and disability worldwide. The permanent loss of heart muscle cells—known as cardiomyocytes—and the heart’s limited regenerative capacity often lead to chronic heart failure. Current treatment strategies manage symptoms but do not repair the underlying damage.
In a first-of-its-kind clinical trial, UCLA scientists have shown it’s possible to reprogram a patient’s blood-forming stem cells to generate a continuous supply of functional T cells, the immune system’s most powerful cancer-killing agents.
A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models of ovarian cancer, outperforming the current gold standard.
A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key driver in T-cell development and function.